Hiro is a Research Analyst at Vestal Point, where he primarily covers pre-commercial-stage therapeutic companies. Prior to joining Vestal Point, he was an Equity Research Associate at Cantor Fitzgerald from 2023 to 2025, focusing on biotechnology. He graduated from the University of Pennsylvania with a B.A. in Biology and a B.S.E. in Finance.